Literature DB >> 1477804

Approaches for genetic purity testing of live recombinant viral vaccines using a human adenovirus:rabies model.

C Lutze-Wallace1, T Sapp, S A Nadin-Davis, A Wandeler.   

Abstract

A two part purity testing regimen for genetically engineered live viral vaccines is described using a human adenovirus 5: rabies glycoprotein gene recombinant as a model vaccine. Initially, restriction endonuclease analysis of the recombinant viral genome verified the integrity of the recombinant construct and identified the vector genome. The second stage employed the polymerase chain reaction to facilitate a more detailed study of the target rabies glycoprotein cassette. The size of the target region was predicted from known nucleic acid sequence information and compared to that obtained after electrophoresis with molecular weight standards. Digestion of the polymerase chain reaction product with a second restriction endonuclease cleaved the target into a number of small fragments. Resolution of the fragments by gel electrophoresis allowed analysis of the target region alone, verifying its identity and integrity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1477804      PMCID: PMC1263569     

Source DB:  PubMed          Journal:  Can J Vet Res        ISSN: 0830-9000            Impact factor:   1.310


  16 in total

1.  Efficacy studies on a canarypox-rabies recombinant virus.

Authors:  J Taylor; C Trimarchi; R Weinberg; B Languet; F Guillemin; P Desmettre; E Paoletti
Journal:  Vaccine       Date:  1991-03       Impact factor: 3.641

2.  A method to detect ras point mutations in small subpopulations of cells.

Authors:  J Chen; M V Viola
Journal:  Anal Biochem       Date:  1991-05-15       Impact factor: 3.365

3.  Current approaches to vaccine preparation.

Authors:  J J Liu; A Cepica
Journal:  Can Vet J       Date:  1990-03       Impact factor: 1.008

4.  Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia.

Authors:  R K Saiki; S Scharf; F Faloona; K B Mullis; G T Horn; H A Erlich; N Arnheim
Journal:  Science       Date:  1985-12-20       Impact factor: 47.728

5.  DNA restriction analysis of adenovirus prototypes 1 to 41.

Authors:  T Adrian; G Wadell; J C Hierholzer; R Wigand
Journal:  Arch Virol       Date:  1986       Impact factor: 2.574

6.  Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique.

Authors:  S Levi; A Urbano-Ispizua; R Gill; D M Thomas; J Gilbertson; C Foster; C J Marshall
Journal:  Cancer Res       Date:  1991-07-01       Impact factor: 12.701

7.  Structure of the glycoprotein gene in rabies virus.

Authors:  A Anilionis; W H Wunner; P J Curtis
Journal:  Nature       Date:  1981-11-19       Impact factor: 49.962

8.  Modified-live infectious bovine rhinotracheitis virus vaccine expressing monomer and dimer forms of foot-and-mouth disease capsid protein epitopes on surface of hybrid virus particles.

Authors:  S Kit; M Kit; R D DiMarchi; S P Little; C Gale
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

9.  A recombinant human adenovirus vaccine against rabies.

Authors:  L Prevec; J B Campbell; B S Christie; L Belbeck; F L Graham
Journal:  J Infect Dis       Date:  1990-01       Impact factor: 5.226

10.  Expression of rabies virus glycoprotein from a recombinant vaccinia virus.

Authors:  M P Kieny; R Lathe; R Drillien; D Spehner; S Skory; D Schmitt; T Wiktor; H Koprowski; J P Lecocq
Journal:  Nature       Date:  1984 Nov 8-14       Impact factor: 49.962

View more
  1 in total

1.  In vitro assessments of the genetic stability of a live recombinant human adenovirus vaccine against rabies.

Authors:  C Lutze-Wallace; T Sapp; M Sidhu; A Wandeler
Journal:  Can J Vet Res       Date:  1995-04       Impact factor: 1.310

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.